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There are high levels of comorbidity between neuropsychiatric and cardiovascular disorders. A key molecule central to both
cognitive and cardiovascular function is the molecule serotonin. In the brain, serotonin modulates neuronal activity and is
actively involved in mediating many cognitive functions and behaviors. In the periphery, serotonin is involved in vasoconstriction,
inﬂammation, and cell growth, among other processes. It is hypothesized that one component of the serotonin system, the 5-HT2A
receptor,isacommonandcontributingfactorunderlyingaspectsofthecomorbiditybetweenneuropsychiatricandcardiovascular
disorders. Within the brain this receptor participates in processes such as cognition and working memory, been implicated in
eﬀective disorders such as schizophrenia, and mediate the primary eﬀects of hallucinogenic drugs. In the periphery, 5-HT2A
receptors have been linked to vasoconstriction and hypertension, and to inﬂammatory processes that can lead to atherosclerosis.
Copyright © 2009 Charles D. Nichols. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Neuropsychiatric disorders have high levels of comorbidity
with cardiovascular disease. A recent retrospective study
indicates that metabolic syndrome was reported in about
40% of schizophrenic patients, 35% of bipolar patients, and
25% of patients with recurrent depression [1]. Environ-
mental factors, including medications, likely underlie some
of the metabolic dysfunction associated with schizophrenia
and depression, however, studies in unmedicated drug na¨ ıve
ﬁrst episode schizophrenics indicate that a pathological
association exists [2]. Signiﬁcantly, many other studies have
also linked metabolic syndrome, cardiovascular disease, and
psychiatric disorders [3–7], and speciﬁc aspects of cardio-
vascular disease like atherosclerosis and hypertension are
associated with psychiatric disorders [8–10]. Patients with
schizophrenia have an average reduction in life expectancy
of 15 years, largely due to coronary heart disease [11].
Unfortunately, many therapeutics used to treat psychiatric
disorders can have signiﬁcant negative inﬂuences on aspects
of cardiovascular function and have thus clouded the nature
of these links with regard to cause and eﬀect. Antipsychotic
medications, as well as therapeutics for other psychiatric dis-
orders, can have dramatic eﬀects on metabolic processes and
can induce metabolic syndrome, weight gain, and diabetes,
which are all signiﬁcant risk factors for the development
of cardiovascular diseases [12–15]. Furthermore, prolon-
gation of the interval between ventricular depolarization
and repolarization (QT interval) also has been associated
with antipsychotic medications [16]. Overall, metabolic and
cardiovascular dysfunction associated with neuropsychiatric
disorders, therefore, likely represent a mixture of environ-
mental, medication, and pathological factors.
Whereas the exact biochemical nature of the links
between cardiovascular disease and psychiatric disorders
remains elusive, it is evident that there is a strong association
between these biological processes. The fact that medications
used to treat one condition can inﬂuence, and even induce,
the other condition underscores these associations. With
respect to depression, models have been proposed that
largely invoke an underlying dysregulation of the HPA axis,
which through modulation of factors such as cortisol and
CRF inﬂuence mood, aﬀect, immunity, and cardiovascular
function [6, 17, 18].
Aspects of cardiovascular disease including endothelial
dysfunction and atherosclerosis are acutely mediated by
inﬂammatory mechanisms. For example, adipose tissues can
release proinﬂammatory cytokines into the circulation. As
moreadiposetissuesarepresentinanindividual,represented
by a higher body mass index, more cytokines can be released.2 Cardiovascular Psychiatry and Neurology
These cytokines, primarily Tumor Necrosis Factor-α (TNF-
α) and IL6, can directly induce inﬂammation in cardio-
vascular tissues, as well as activate the HPA axis, which in
turn can lead to metabolic syndrome. Metabolic syndrome
can subsequently lead to oxidative stress and generation
of free radicals that together induce further production of
proinﬂammatory cytokines, and the two processes of inﬂam-
mation and metabolic syndrome can interact synergistically
to elevate levels of proinﬂammatory cytokines and promote
further endothelial dysfunction and atherosclerosis [19].
A detailed review of the development and progression of
atherosclerosis itself will not be given here, and the reader
is referred to other reviews and references therein [20, 21].
A key mediator of the development of atherosclerosis is
the cytokine TNF-α which, acting through its receptors on
the surface of macrophage, endothelial, and smooth muscle
cells of the vasculature, induces signal transduction cascades
leading to NOS activity, activation of transcription factors
such as Nuclear Factor kappa B (NF-κB), and production
of proinﬂammatory adhesion molecules and cytokines such
as ICAM-1, VCAM-1, and IL6. Together, these processes
facilitate macrophage inﬁltration of the arterial wall, diﬀer-
entiation of macrophages to lipid-accumulating foam cells,
and migration of arterial smooth muscle cells to form a
ﬁbrous cap, together constituting the atherosclerotic plaque.
Severe cases cause signiﬁcant blockage of the artery, and
eventual rupture of the plaque and thrombosis.
Recently, cytokine-mediated inﬂammation has been
implicated in the development and presentation of psychi-
atric disorders that include depression and psychosis [22–
24]. In major depression and bipolar disease, increases in
TNF-α, and other proinﬂammatory cytokines (e.g., IL6,
and other proinﬂammatory molecules such as ICAM-1 and
MCP-1),havebeenfoundwithintheCNS[23,25].Although
the association of inﬂammation with depression does not
necessarily imply causality, certain symptoms of depression
have been shown in both clinical studies and animal models
to be alleviated by anti-inﬂammatory therapeutics [26].
Interestingly,knockoutmicelackingTNF-αreceptorsexhibit
antidepressant-like behaviors in several types of assays [27].
Neuroinﬂammation leading to dysfunction of the adult
CNS as well as inﬂammatory events in utero leading to
perturbation of normal synaptic development has been
proposed as possible factors contributing to psychiatric
disorders [23, 24].
It has long been recognized that 5-hydroxytryptamine
(serotonin; 5-HT), and its biosynthetic precursor tryp-
tophan, play an important role in regulating immune
functions through non-5-HT receptor interactions involving
circulating tryptophan and kynurenine levels [28–30]. Indi-
vidual serotonin receptors, however, are expressed in many
immune-relatedtissues,andinteractionsatspeciﬁcreceptors
are also known to modulate aspects of the immune response
and inﬂammation [31–33]. Within the CNS, serotonin
and serotonin receptors have been strongly associated with
normal function. Certain neuropsychiatric disorders that
include depression, bipolar disorder, OCD, anorexia, and
schizophrenia have been linked to dysregulation of CNS
serotonin [34, 35]. Indeed, therapeutics for these disorders
often include inhibition of the serotonin transporter (SERT)
with selective serotonin reuptake inhibitor (SSRI) medica-
tions, or blockade of speciﬁc serotonin receptor subtypes.
SSRIs can also show an eﬃcacy in treating aspects of
cardiovascular disease associated with depression [36], and
have been demonstrated in animal models to have an anti-
inﬂammatory eﬀect [37]. The mechanisms underlying the
protective eﬀect of antidepressants are not precisely known,
but are predicted by some researchers to involve activation
of the pituitary-adrenocortical system via increased central
serotonin levels [38], by modulation of cytokine levels in
peripheral tissues [39, 40], and by suppression of platelet
activation [41]. Furthermore, acute SSRI administration has
been shown to have a vasodilatory eﬀect on the coronary
artery that may be cardioprotective [42]. Interestingly, TNF-
α, as well as certain other cytokines, have been shown
to inﬂuence both expression and transport activity of the
serotonin transporter. In neuronally derived cells and chori-
ocarcinoma cells, TNF-α,I N F - γ,a n dI L 1 β increase function
[43–45], whereas in B lymphocytes, IL4 decreases function
[46], and in intestinal epithelial derived Caco-2 cells, TNF-
α has been found to decrease both expression and transport
activity of SERT [47]. Whereas the nature of the inﬂuence of
cytokines on SERT function (e.g., facilitation or repression)
likely depends on the cytokine and tissue, modulation
of synaptic serotonin levels in various brain regions by
inﬂammatory cytokines would certainly be anticipated to
havesomeeﬀectonneuronalfunctionrelevanttopsychiatric
disorders like depression. In summary, there appears to be
a strong link between proper functioning and regulation of
the serotonin system and factors underlying cardiovascular
disease and neuropsychiatric disorders.
We hypothesize that a particular aspect of the serotonin
system, the 5-HT2A receptor, is a common and contributing
factor underlying aspects of normal cardiovascular and CNS
function, and that dysfunction of this receptor results in
certaincharacteristicsofcardiovascularandneuropsychiatric
disorders. There are seven families of serotonin receptors
comprised of fourteen distinct subtypes [48]. With the
exception of the 5-HT3 receptor, which is a ligand-gated ion
channel, all are seven transmembrane-spanning G-protein-
coupled receptors. Of all the serotonin receptors, the 5-
HT2A receptor has been the one most closely linked to
complex behaviors and neuropsychiatric disorders. The 5-
HT2A receptor is highly expressed within the frontal cortex,
withlowerexpressionlevelsthroughoutthebrain[48].There
has been extensive research performed to establish the role
of 5-HT2A receptors within the brain, where they have been
shown to participate in processes such as cognition and
working memory [49], mediate the primary eﬀects of hal-
lucinogenic drugs [50], and been implicated in mechanisms
underlying schizophrenia [51, 52]. Furthermore, abnormal
expression of 5-HT2A receptors has also been linked to
depression. For example, some studies have shown that
receptor protein expression is increased in certain cortical
areas of patients with major depression [53, 54], as well
as suicide victims [55, 56]. 5-HT2A receptor expression
decreases, however, have been found in brain limbic regions
of patients with major depressive disorder [57].Cardiovascular Psychiatry and Neurology 3
Signiﬁcantly, 5-HT2A receptors are found outside the
CNS in many diverse tissues, including those related to
cardiovascular function. Their role in the periphery, how-
ever, is less clear. Also, 5-HT2A receptor mRNA is expressed
within vascular smooth muscle and endothelial cells, and
cardiomyocytes, where the receptors are believed to mediate
aspects of vasoconstriction and cellular proliferation [58–
60]. Not only can 5-HT2A receptor activity modulate cardio-
vascular function in the periphery, but it has been found to
act centrally: activation of 5-HT2A receptors in the nucleus
tractus solitarius of the brain dramatically lowers both blood
pressure and heart rate [61].
Recently, we have found that selective activation of 5-
HT2A receptors in primary aortic smooth muscle inhibits
TNF-α-mediated inﬂammatory markers with extraordinary
potency. With an IC50 value of about 10 picomolar, 5-
HT2A receptor activation with the drug (R)-DOI inhibits
NOS activity, the activation and nuclear translocation of the
p65 subunit of NF-κB, as well as the production of mRNA
for the proinﬂammatory cell adhesion proteins ICAM-1
and VCAM-1, and mRNA for the cytokine IL6 [33]. Other
chemically diverse molecules that activate 5-HT2A recep-
tors, including the hallucinogen lysergic acid diethylamide
(LSD), also have potent anti-inﬂammatory eﬀects on aortic
smooth muscle in vitro [33], indicating that this is a
property of 5-HT2A receptor activation and not speciﬁc to
a particular drug. Signiﬁcantly, we have found potent anti-
inﬂammatory eﬀects in primary aortic endothelial cells as
well as macrophages (unpublished data). TNF-α signaling in
these three cell types, aortic smooth muscle, endothelial, and
macrophage, is believed to be a major contributing factor
to the inﬂammatory processes underlying the development
and progression of atherosclerosis. As such, drugs acting
at 5-HT2A receptors, like (R)-DOI, may represent a novel
class of superpotent small molecule inhibitors of TNF-α
pathway signaling with therapeutic potential for treating not
only atherosclerosis but also other inﬂammatory conditions
involving TNF-α, that are more then 100-fold more potent
thanthemorepotentsteroidalanti-inﬂammatoriescurrently
on the market. Importantly, we have also found potent
anti-inﬂammatory eﬀects of 5-HT2A receptor activation in
CNS-related cell culture systems, including C6 glioma, and
SH-SY5Y neuroblastoma cells (unpublished data), indicat-
ing that the role of 5-HT2A receptors in mediating anti-
inﬂammatory pathways is not limited to cardiovascular
tissues, but is likely relevant in the CNS.
As mentioned previously, drugs that interact with or
inﬂuence 5-HT2A receptor function can dramatically aﬀect
aspects of cardiovascular function. Some, including atypical
antipsychotic, medications have a negative inﬂuence, while
others, including ketanserin and certain antidepressants, are
reported to have a beneﬁcial cardiovascular eﬀect. How do
these eﬀects ﬁt within the framework of our hypothesis?
Ketanserin has been eﬀective in the clinic as an anti-
h y p e r t e n s i v ea g e n ta sw e l la sa na n t i a r r h y t h m i c .I tc a n
also sometimes induce proarrhythmias, and was withdrawn
from the market largely for this reason. Recent reports
suggest that the antiarrhythmic eﬀects of ketanserin may be
due to direct interactions with certain potassium channels,
including the HERG channel, and not to blockade of the 5-
HT2A receptor per se [62–64]. With regards to ketanserin’s
use as an antihypertensive, the underlying mechanisms are
not entirely clear as ketanserin has signiﬁcant aﬃnity for
the alpha-1 adrenergic receptor, and many reports have
cited this as the putative antihypertensive therapeutic target
rather than antagonism of the 5-HT2A receptor [58, 65,
66]. Nevertheless, many in vitro studies of 5-HT2A receptor
antagonists have clearly demonstrated that 5-HT-induced
vasoconstriction in isolated vascular tissue preparations is
in large part mediated by 5-HT2A receptors [60]. Although
blockade of 5-HT2A receptors can potently inhibit serotonin-
mediated vasoconstriction in isolated vascular preparations,
aside from ketanserin, other 5-HT2A receptor antagonists
show little to no antihypertensive eﬀect in vivo [66, 67].
Indeed, newer highly selective 5-HT2A receptor antagonists,
like M100907 (volinanserin), ACP-103 (primavanserin), and
SR46349B (eplivanserin), are currently in clinical trials as
novel therapeutics to treat insomnia [68] and there are
no reports in literature describing eﬀects on hypertension,
inﬂammation,orothercardiovascularprocesses.Onereport,
however, examining the physiological and pharmacokinetics
of ACP-103 in a small study comprised of normal human
subjects has been published that concluded that there were
no signiﬁcant changes in vital signs or ECG associated with
treatment for up to fourteen days [69].
An interesting study recently published detailed the
eﬀects of chronic increases in circulating serotonin levels, as
opposed to large bolus doses. It was predicted that, as occurs
withabolusdoseofserotonin,bloodpressurewouldincrease
due to the vasoconstrictive eﬀects of increased 5-HT acting
at 5-HT2 receptors. It was found that increased circulating
5-HT levels actually signiﬁcantly decreased blood pressure
[70, 71]. The author of this study stated that it was unlikely
that direct activation of vasoralaxant 5-HT receptors was
responsibleforthiseﬀect,andthatfurtherstudiesareneeded
to elucidate underlying mechanisms [70]. If antagonism
of 5-HT2A r e c e p t o r si se x p e c t e dt op r o d u c eh y p o t e n s i o n
and aﬀect cardiac rhythmicity, then activation would be
anticipated to produce hypertension and potentially aﬀect
rhythmicity. This has not been the case. In humans, the
5-HT2A receptor agonist, psilocybin, which also has high
aﬃnity for 5-HT1A receptors, produces only mild and tran-
sient cardiovascular eﬀects at high doses when administered
systemically. Highly hallucinogenic doses (e.g., 30mg) only
produce minor and transient increases in baseline heart
rate (+10bpm) and blood pressure (∼15%) and do not
inﬂuence heart function as measured by electrocardiogram
[72–74]. Lower non-hallucinogenic doses of psilocybin do
notproducesigniﬁcantchangesinheartrate,bloodpressure,
or heart function [72–74]. Another 5-HT2A receptor agonist
dimethyltryptamne (DMT) has been given to humans at
highly hallucinogenic doses [75]. In that study, intravenous
injection of DMT was found to only elicit minor and very
transient increases in heart rate and blood pressure [75]. It
should be noted that some of these increase can probably
be attributed to psychological stress and anxiety produced
by the hallucinogenic eﬀects of psilocybin and DMT at high
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pressure or heart rate. There have been no studies reported
examining the eﬀects of chronic administration of 5-HT2A
receptor agonists in mammals. It will be interesting to see
in future experiments if chronic administration of these
agents aﬀects inﬂammation-related cardiovascular diseases
orotheraspectsofcardiovascularfunction.Ourdataindicate
that potential anti-inﬂammatory eﬀects of agonists like (R)-
DOI would be evident at doses far below that necessary
to elicit behavioral eﬀects like hallucinations. Interestingly,
there are antidepressant-like eﬀects associated with single
hallucinogenic doses of psilocybin [73, 76].
Atypical antipsychotic medications like olanzapine,
clozapine, and risperidone belong to a newer class of drug
that are believed to have a component of their therapeutic
eﬀect mediated by antagonism of 5-HT2A receptors [77].
Unliketraditionalantipsychoticmedicationslikehaloperidol
that act primarily as antagonists at dopamine D2 receptors,
atypical antipsychotics have some eﬃcacy at treating the
negative, or more cognitive, symptoms of schizophrenia, and
this may be due to their eﬀects on 5-HT2A receptors. As pre-
viously mentioned, pathological associations exist between
schizophrenia and metabolic syndrome and cardiovascular
disorders, however, the use of atypical antipsychotics is,
unfortunately, strongly associated with the development
of signiﬁcant weight gain, metabolic, and cardiovascular
disorders [14, 15, 78]. The substantial weight gain asso-
ciated with atypical antipsychotics is believed to partially
involve antagonist or inverse agonist activity of these drugs
at 5-HT2C receptors [79]. Indeed, the 5-HT2C knockout
mouse is severely obese [80], and agonists of this receptor
can produce hypophagia [81]. Although many aspects
of metabolic and cardiovascular disorders associated with
atypical antipsychotics are likely a direct consequence of
weight gain, other aspects may be mediated by blockade of
5-HT2A receptor function. For example, 5-HT2A receptors
have been implicated in regulation of glucose homeostasis
[82, 83], and antagonism of the 5-HT2A receptor may
inﬂuence insulin sensitivity [84, 85]. Within the framework
of our hypothesis, aberrant 5-HT2A receptor function may
contribute to both psychosis and pathological association
of metabolic and cardiovascular disorders. This dysfunction
could result in hyperacticvity in the CNS, and contribute
to psychosis. In the periphery, receptor dysfunction may
promote processes leading to metabolic disorder and car-
diovascular disease through largely unexplored mechanisms.
Whereas blockade of 5-HT2A receptor hyperfunction in
the CNS may be therapeutic for treating psychosis, recep-
tor blockade, both in the CNS and periphery, may also
interfere with endogenous anti-inﬂammatory processes and
synergistically act with the eﬀects of induced weight gain
to produce signiﬁcant metabolic and cardiovascular disor-
ders.
Another class of medication that aﬀects psychiatric
disorders, inﬂammatory processes, and cardiovascular func-
tion is selective serotonin reuptake inhibitor antidepressants
(SSRIs). Interestingly, SSRI antidepressant medications have
a biphasic eﬀect on serotonin within the brain. Acute
treatment leads to decreased serotonin release, and chronic
treatment leads to increased release [86, 87]. The acute
decrease in 5-HT release results from autoreceptor acti-
vation and subsequent inhibition of release and synthesis
of serotonin. As these receptors desensitize with chronic
SSRI treatment, however, overall 5-HT transmission is
facilitated. Chronic treatment with SSRI antidepressants also
has been shown to produce signiﬁcant downregulation and
desensitization of 5-HT2A receptors both in vitro and in
vivosimilartochronictreatmentwithatypicalantipsychotics
[88]. The eﬀects of SSRI induced receptor desensitization
and downregulation would be anticipated to mimic the
eﬀects of chronic treatment with atypical antipsychotics,
and reduce overall 5-HT2A receptor function. Within the
framework of our model, these eﬀects would be predicted
to produce a deﬁcit in receptor function, and increases in
proinﬂamatorymechanismspotentiallyleadingtocardiovas-
cular disease, metabolic disorders, and neuroinﬂammation.
SSRI antidepressants, however, have been shown to have
anti-inﬂammatory activity and to be cardioprotective when
given both acutely and chronically. It is conceivable that
the acute anti-inﬂammatory and cardioprotective eﬀects of
SSRI antidepressants are mediated by mechanisms other
than manipulation of 5-HT2A receptor function, as discussed
previously, and the beneﬁcial eﬀects of chronic treatment
may involve enhanced 5-HT tone at 5-HT2A receptors.
Although chronic treatment with SSRI antidepressants
produces desensitization and downregulation of 5-HT2A
receptors, our results demonstrate that 5-HT2A receptors in
this state are actually more sensitive to the anti-inﬂammatory
eﬀects of activation by the agonist (R)-DOI by an order
of magnitude [33]. Together, the anti-inﬂammatory and
cardioprotective eﬀects of SSRI antidepressants are, there-
fore, likely a combination of direct modulation of cytokines,
central action within the CNS, and modulation of 5-
HT2A receptor function, with each component contributing
diﬀerently as therapy progresses to achieve a steady state.
Here, we propose that deﬁcits in 5-HT2A receptor
function underlie at least part of the comorbidity of
cardiovascular disease and neuropsychiatric disorders. If
5-HT2A receptor activation normally appears to exert a
powerful anti-inﬂammatory inﬂuence on a variety of cells,
especially vascular tissues, dysfunction may be anticipated
to lead to a repression of anti-inﬂammatory inﬂuences and
to the expression of proinﬂammatory markers, sensitiza-
tion of the cell to inﬂammatory stimuli, or both, leading
to an increased risk of inﬂammation and atherosclerosis.
Similarly, 5-HT2A receptor dysfunction also may contribute
to increased risk of hypertension, and cardiac hypertro-
phies within the cardiovascular system. Unfortunately, there
are few, if any, studies reported in literature examining
expression levels of 5-HT2A receptors in diseased cardio-
vascular related tissues. This simply may be due to the
fact that no one has looked. If so, then examination
of receptor levels in diseased cardiovascular-related tis-
sues may be a productive avenue of exploration. In rat
models of congestive heart failure, there are two reports
demonstrating increased levels of 5-HT2A receptor mRNA
[59, 89]. It remains to be determined if the increased
expression is causative, or a compensatory response to other
factors.Cardiovascular Psychiatry and Neurology 5
Within the CNS, the same receptor dysfunction may
result in or contribute to the development of neuropsy-
chiatric disorders including depression, bipolar disease,
and psychosis. This dysfunction may either come from
alterations in regulation due to promoter polymorphisms
or other regulatory mechanisms inﬂuencing expression, or
polymorphisms or mutations aﬀecting the protein itself
that could inﬂuence responsiveness and downstream signal
transduction pathways. Polymorphisms in the promoter
region of the human HTR2A locus have been shown
to alter receptor expression levels [90], and these same
polymorphismshavebeenlinkedtoresponsetoantisychotics
and certain SSRIs [91, 92], and in some studies positively
associated with various CNS conditions including major
depression, bipolar disorder, and schizophrenia [93–96].
Signiﬁcantly, positive associations also have been detected
for these polymorphisms and symptoms of cardiovascular-
related disorders [97]. Polymorphisms within the coding
regions of the HTR2A locus have been found in some studies
to be positively associated with neuropsychiatric disorders,
as well as to rheumatoid arthritis [98], circulating cholesterol
levels [99], hypertension [100], myocardial infarction [101],
as well as blood pressure and metabolic syndrome [102].
There is signiﬁcant opportunity for future research to
investigate how 5-HT2A receptor function mediates certain
aspects of both neuropsychiatric and cardiovascular-related
disorders. Greater clariﬁcation of the role of receptor antag-
onists in vivo is needed. This could involve examining the
eﬀects of the new highly selective receptor antagonists in
rodent models of cardiovascular disease and atherosclerosis,
as well as careful examination of clinical trial data for the use
of these drugs as sleep aids and continued analysis for the
eﬀects of chronic use on cardiovascular-related issues after
these therapeutics come to market. Not only could results
fromthesetypesofstudiesbeinformativeabouttheeﬀectsof
selectivereceptorblockadeoncardiovascular-relateddiseases
but they could also help to address the question of whether
or not the negative cardiovascular and metabolic eﬀects of
atypical antipsychotics have a signiﬁcant 5-HT2A receptor-
mediated component. If they did, then perhaps long-term
therapy with these new highly selective receptor antagonists
would produce metabolic and cardiovascular disorders. In
our laboratory, we are continuing to study the eﬀects of
agonists on inﬂammation-related cardiovascular processes,
and attempting to elucidate the molecular mechanisms
underlying their anti-inﬂammatory eﬀects. An additional
resource that would beneﬁcial to explore is the 5-HT2A
receptor knockout mouse model. Amazingly, given the
widespread expression and importance of the 5-HT2A recep-
tor, the knockout animal appears overtly normal. There are,
however,certainbehavioraleﬀectsassociatedwithlossofthis
receptor [103, 104]. Interestingly, some observed behaviors
are opposite to the eﬀects of receptor antagonists [105],
indicating that caution should be exercised in the interpre-
tation of knockout studies using this model. Nevertheless,
studies utilizing this mouse in models of cardiovascular-
relateddiseaseswilllikelybeofvalue.Abetterunderstanding
of the relationship between 5-HT2A receptor function and its
roles in both the CNS and cardiovascular system should lead
to development of improved therapeutics to treat diseases
aﬀecting each of these systems either separately or together.
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